Sidebar ... I do believe things are going on behind the scenes.

I think Hepa's approach to the debenture recently is likely evidence of that "probability." There are still articles and papers appearing. Volumes have been up lately.

It's just so frustrating that the pps is still sooo low, no material news of interest, or communication from leadership, etc. I also still believe there is just too much promise with the safety and science for this to be a complete abject failure as far as eventually getting to market in one way or another. The failure is on the end of process, advancement, and communication on the part of leadership. But I am pretty sure communication is solid for the 70% that keep the lights on, we are just in the trailer for the "ride" and hopeful upside opportunity.

With a few minor and small adjustments, and perhaps a little more cash and better decision making, we all likely would have cashed out of RVX at $15-20(+) in 2019. The science and safety is still just as good as it was then, and even better understood. And the studies (i.e. BoM2, etc) being contemplated seem better designed and more on target than BoM.

It's just frustrating that almost 4 years later, no real and apparent progress, or significantly encouraging information, and we sit at $.10 U.S.

Still long, and I would say "strong" but "stuck" is more accurate lol ... but still hopeful given the science and safety. Just hope I am still alive to see it all happen someday.

And who knows, I am healthy but ain't getting any younger, the medication may even be helpful for me personally, someday.